RxSight, Inc. (NASDAQ:RXST) Shares Acquired by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership grew its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 32.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,551,620 shares of the company's stock after acquiring an additional 381,389 shares during the quarter. Artisan Partners Limited Partnership owned about 3.85% of RxSight worth $53,345,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Quarry LP grew its holdings in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company's stock valued at $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd purchased a new stake in shares of RxSight in the 3rd quarter valued at approximately $34,000. Private Trust Co. NA acquired a new stake in shares of RxSight during the 4th quarter worth approximately $34,000. Arcadia Investment Management Corp MI purchased a new stake in shares of RxSight during the 4th quarter valued at approximately $46,000. Finally, Harbor Investment Advisory LLC acquired a new position in RxSight in the fourth quarter valued at approximately $52,000. Hedge funds and other institutional investors own 78.78% of the company's stock.

Insider Buying and Selling

In related news, Director Shweta Maniar sold 3,519 shares of RxSight stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the sale, the director now owns 7,383 shares in the company, valued at approximately $227,913.21. This trade represents a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jesse Anderson Corley acquired 1,443 shares of RxSight stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the purchase, the director now directly owns 1,443 shares of the company's stock, valued at approximately $44,992.74. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 9.36% of the stock is currently owned by insiders.

Remove Ads

Analyst Ratings Changes

RXST has been the topic of several recent analyst reports. UBS Group began coverage on RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 price target on the stock. Stifel Nicolaus decreased their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. JPMorgan Chase & Co. dropped their price target on shares of RxSight from $62.00 to $40.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company reduced their price target on shares of RxSight from $40.00 to $35.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $43.00 price objective on shares of RxSight in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, RxSight currently has a consensus rating of "Moderate Buy" and an average price target of $49.33.

RxSight Stock Down 4.6 %

RXST traded down $1.22 during trading on Monday, hitting $25.34. 237,898 shares of the stock were exchanged, compared to its average volume of 550,672. RxSight, Inc. has a 1-year low of $24.09 and a 1-year high of $66.54. The stock has a fifty day moving average price of $29.10 and a two-hundred day moving average price of $38.96. The firm has a market capitalization of $1.03 billion, a P/E ratio of -30.67 and a beta of 1.22.

RxSight (NASDAQ:RXST - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. Analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.